Anticipated Impact of Generic Imatinib Market Entry on the Costs of Tyrosine Kinase Inhibitors

Podobne knjige/članki

• Realized and Projected Cost-Savings from the Introduction of Generic Imatinib Through Formulary Management in Patients with Chronic Myelogenous Leukemia
  od: Campbell, David, et al.
  Izdano: (2019)
• Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States
  od: Padula, William V., et al.
  Izdano: (2016)
• Expenditures for First- and Second-Generation Tyrosine Kinase Inhibitors Before and After Transition of Imatinib to Generic Status
  od: Kenzik, Kelly M., et al.
  Izdano: (2020)
• Association of Generic Imatinib Availability and Pricing With Trends in Tyrosine Kinase Inhibitor Use in Patients With Chronic Myelogenous Leukemia
  od: Lyman, Gary H., et al.
  Izdano: (2020)
• Impact of Long-Term Exposure to the Tyrosine Kinase Inhibitor Imatinib on the Skeleton of Growing Rats
  od: Tauer, Josephine T., et al.
  Izdano: (2015)